Show simple item record

dc.contributor.authorSade, Juan P.
dc.contributor.authorMaluf, Fernando.
dc.contributor.authorToledo, Felipe.
dc.contributor.authorEt al.
dc.date.accessioned2023-06-16T15:15:00Z
dc.date.available2023-06-16T15:15:00Z
dc.date.issued2021-04
dc.identifier.citationJCO Glob Oncol . 2021 Apr;7:559-571.es
dc.identifier.issn2687-8941
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/2199
dc.identifier.urihttps://ascopubs.org/doi/10.1200/GO.20.00511?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
dc.descriptionDisponible en: https://ascopubs.org/doi/pdf/10.1200/GO.20.00511?role=tabes
dc.description.abstractAbstract Purpose: To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. Methods: A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and response to prior drug treatments, appropriate drug treatments, and follow-up, and those same scenarios when limited resources needed to be considered. Responses were compiled and the percentages were presented by clinicians to support each response. Most questions had five to seven relevant options for response including abstain and/or unqualified to answer, or in the case of yes or no questions, the option to abstain was offered. Results: Most of the recommendations from this panel were in line with prior consensus, including the preference of a new antiandrogen for first-line therapy of mCRPC. Important aspects highlighted in the scenario of limited resources included the option of docetaxel as treatment preference as first-line treatment in several scenarios, docetaxel retreatment, consideration for reduced doses of abiraterone, and alternative schedules of an osteoclast-targeted therapy. Conclusion: There was wide-ranging consensus in the treatment for men with mCRPC in both optimal and limited resource settings.es
dc.language.isoenes
dc.publisherAmerican Society of Clinical Oncologyes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCanceres
dc.subjectOncology.es
dc.subjectProstate Canceres
dc.titleConsensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)es
dc.typeArticlees


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional